patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_443742 | REC_0001001 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.6 | 72 | female | 1 | 14 | 5.7 | 2 | sotorasib 960 mg daily | 7.7 | false | MSS | 2026-03-15T05:35:57.088876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418434 | REC_0001002 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 14.9 | 81 | female | 1 | 22 | 7.4 | 8 | sotorasib 960 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:57.089191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141213 | REC_0001003 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 11.3 | 81 | female | 4 | 18 | 7.1 | 1 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:57.089471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467760 | REC_0001004 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 5.3 | 61 | female | 0 | 19 | 6.5 | 5 | osimertinib 80 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:57.089722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280726 | REC_0001005 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 7.3 | 66 | female | 1 | 51 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.4 | true | MSS | 2026-03-15T05:35:57.089964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918916 | REC_0001006 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 8.6 | 76 | female | 0 | 18 | 5.9 | 7 | entrectinib 600 mg daily | 6.5 | false | MSS | 2026-03-15T05:35:57.090202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408730 | REC_0001007 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 8.2 | 81 | male | 1 | 13 | 5.5 | 5 | entrectinib 600 mg daily | 6 | false | MSS | 2026-03-15T05:35:57.090438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490850 | REC_0001008 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 15.1 | 60 | female | 0 | 20 | 8 | 4 | alectinib 600 mg BID | 11.3 | false | MSI-H | 2026-03-15T05:35:57.090672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217675 | REC_0001009 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 17.7 | 65 | female | 1 | 8 | 4.9 | 2 | alectinib 600 mg BID | 17.3 | false | MSI-H | 2026-03-15T05:35:57.090909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_348564 | REC_0001010 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 13.5 | 67 | female | 0 | 17 | 6.5 | 4 | osimertinib 80 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:35:57.091145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382659 | REC_0001011 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 5.2 | 67 | female | 0 | 87 | 4.6 | 1 | pembrolizumab 200 mg q3w | 17.8 | false | MSS | 2026-03-15T05:35:57.091378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791611 | REC_0001012 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 11.7 | 76 | female | 1 | 22 | 5.4 | 1 | osimertinib 80 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:57.091611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980762 | REC_0001013 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 8.8 | 62 | female | 0 | 9 | 4.7 | 7 | entrectinib 600 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:57.091844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531674 | REC_0001014 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 14.5 | 62 | female | 0 | 8 | 2 | 7 | pembrolizumab 200 mg q3w | 8.7 | true | MSI-H | 2026-03-15T05:35:57.092152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367560 | REC_0001015 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 17.4 | 58 | female | 1 | 15 | 6.8 | 5 | sotorasib 960 mg daily | 11.7 | true | MSI-H | 2026-03-15T05:35:57.092511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242553 | REC_0001016 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 15.1 | 59 | male | 1 | 21 | 4 | 2 | entrectinib 600 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:57.092765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403507 | REC_0001017 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 7 | 66 | female | 1 | 44 | 7 | 5 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:57.093000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624704 | REC_0001018 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10.1 | 79 | female | 2 | 13 | 4.6 | 6 | entrectinib 600 mg daily | 5.5 | true | MSI-H | 2026-03-15T05:35:57.093232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690572 | REC_0001019 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 5.8 | 49 | female | 0 | 14 | 5.6 | 5 | osimertinib 80 mg daily | 7.7 | false | MSS | 2026-03-15T05:35:57.093467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536557 | REC_0001020 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 11.6 | 68 | female | 0 | 29 | 6.5 | 0 | sotorasib 960 mg daily | 47.5 | false | MSI-H | 2026-03-15T05:35:57.093707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714871 | REC_0001021 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.1 | 74 | female | 1 | 14 | 6.8 | 4 | osimertinib 80 mg daily | 5.7 | false | MSS | 2026-03-15T05:35:57.093944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342056 | REC_0001022 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 31 | 11.4 | 81 | female | 1 | 14 | 4.9 | 2 | pembrolizumab 200 mg q3w | 28.8 | true | MSI-H | 2026-03-15T05:35:57.094179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938829 | REC_0001023 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 9 | 76 | female | 1 | 8 | 4.7 | 1 | entrectinib 600 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:57.094409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850705 | REC_0001024 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 16.1 | 76 | female | 2 | 20 | 4.1 | 6 | entrectinib 600 mg daily | 13.5 | true | MSI-H | 2026-03-15T05:35:57.094643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434353 | REC_0001025 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 12.4 | 82 | female | 1 | 17 | 6.6 | 0 | sotorasib 960 mg daily | 58.2 | false | MSS | 2026-03-15T05:35:57.094877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307322 | REC_0001026 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 18.7 | 73 | female | 3 | 22 | 5.4 | 2 | entrectinib 600 mg daily | 19.9 | true | MSS | 2026-03-15T05:35:57.095111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698625 | REC_0001027 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 19 | 12.5 | 80 | female | 2 | 18 | 5.9 | 1 | pembrolizumab 200 mg q3w | 21.8 | false | MSS | 2026-03-15T05:35:57.095343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492298 | REC_0001028 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 18.9 | 68 | female | 0 | 26 | 4.1 | 3 | sotorasib 960 mg daily | 8 | true | MSS | 2026-03-15T05:35:57.095652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693179 | REC_0001029 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 6.6 | 73 | female | 1 | 6 | 4.5 | 6 | pembrolizumab 200 mg q3w | 19.5 | true | MSS | 2026-03-15T05:35:57.095895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916769 | REC_0001030 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 4.6 | 67 | female | 2 | 22 | 4.5 | 3 | pembrolizumab 200 mg q3w | 16.5 | true | MSS | 2026-03-15T05:35:57.096171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965225 | REC_0001031 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 16.7 | 69 | female | 1 | 12 | 3.6 | 1 | alectinib 600 mg BID | 26.1 | false | MSS | 2026-03-15T05:35:57.096421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550087 | REC_0001032 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 12 | 69 | female | 0 | 23 | 5.7 | 9 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.096700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725638 | REC_0001033 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 6.9 | 73 | female | 2 | 7 | 6 | 7 | osimertinib 80 mg daily | 7.7 | false | MSS | 2026-03-15T05:35:57.096941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785639 | REC_0001034 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 5.2 | 79 | female | 2 | 23 | 8.5 | 8 | entrectinib 600 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:57.097172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454772 | REC_0001035 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 15.1 | 67 | female | 0 | 10 | 6.2 | 6 | alectinib 600 mg BID | 11.6 | false | MSI-H | 2026-03-15T05:35:57.097405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519792 | REC_0001036 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 5.8 | 70 | female | 0 | 6 | 5.5 | 5 | pembrolizumab 200 mg q3w | 13.9 | false | MSS | 2026-03-15T05:35:57.097634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887589 | REC_0001037 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 15.4 | 68 | female | 0 | 9 | 5.6 | 1 | entrectinib 600 mg daily | 36.3 | false | MSS | 2026-03-15T05:35:57.097875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550494 | REC_0001038 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 15.7 | 61 | male | 0 | 13 | 4.8 | 5 | osimertinib 80 mg daily | 16.8 | true | MSI-H | 2026-03-15T05:35:57.098111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929906 | REC_0001039 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 13.7 | 68 | female | 0 | 9 | 5.1 | 0 | sotorasib 960 mg daily | 32.2 | true | MSS | 2026-03-15T05:35:57.098349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888998 | REC_0001040 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12.1 | 54 | female | 0 | 18 | 6.4 | 5 | entrectinib 600 mg daily | 11.9 | true | MSI-H | 2026-03-15T05:35:57.098585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323989 | REC_0001041 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.8 | 67 | female | 0 | 15 | 6.2 | 5 | sotorasib 960 mg daily | 17.8 | true | MSI-H | 2026-03-15T05:35:57.098922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482120 | REC_0001042 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.2 | 54 | female | 0 | 14 | 6.5 | 7 | sotorasib 960 mg daily | 7.5 | false | MSI-H | 2026-03-15T05:35:57.099188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264124 | REC_0001043 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 4.5 | 66 | female | 1 | 9 | 7.6 | 4 | pembrolizumab 200 mg q3w | 6.4 | false | MSS | 2026-03-15T05:35:57.099443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346611 | REC_0001044 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 12.8 | 50 | female | 0 | 11 | 5.1 | 2 | entrectinib 600 mg daily | 30.2 | false | MSS | 2026-03-15T05:35:57.099699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623457 | REC_0001045 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 14.4 | 66 | female | 0 | 17 | 5.6 | 3 | sotorasib 960 mg daily | 26.3 | false | MSI-H | 2026-03-15T05:35:57.099941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634600 | REC_0001046 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 10.2 | 70 | female | 2 | 8 | 6 | 8 | sotorasib 960 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.100258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165681 | REC_0001047 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 8.3 | 66 | female | 0 | 39 | 4.6 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.5 | true | MSS | 2026-03-15T05:35:57.100513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367235 | REC_0001048 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 24 | 12.3 | 62 | male | 1 | 11 | 5.8 | 0 | pembrolizumab 200 mg q3w | 43.5 | false | MSS | 2026-03-15T05:35:57.100761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795523 | REC_0001049 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 14.5 | 52 | male | 0 | 17 | 6.3 | 6 | entrectinib 600 mg daily | 11.3 | true | MSI-H | 2026-03-15T05:35:57.101003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609091 | REC_0001050 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 14.5 | 59 | female | 1 | 10 | 5.1 | 5 | entrectinib 600 mg daily | 5.8 | true | MSS | 2026-03-15T05:35:57.101243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969277 | REC_0001051 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 11.8 | 64 | female | 0 | 7 | 5.1 | 4 | sotorasib 960 mg daily | 7.7 | false | MSI-H | 2026-03-15T05:35:57.101481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155629 | REC_0001052 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 19 | 4.2 | 80 | male | 1 | 50 | 4.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 41.2 | false | MSS | 2026-03-15T05:35:57.101721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955410 | REC_0001053 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 20.5 | 72 | female | 2 | 14 | 6.8 | 2 | entrectinib 600 mg daily | 23.2 | false | MSI-H | 2026-03-15T05:35:57.101960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572365 | REC_0001054 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 37 | 4.8 | 70 | female | 2 | 33 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.8 | false | MSS | 2026-03-15T05:35:57.102283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309908 | REC_0001055 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 8.2 | 80 | female | 2 | 24 | 7 | 5 | entrectinib 600 mg daily | 7.9 | true | MSS | 2026-03-15T05:35:57.102521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370610 | REC_0001056 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 15.8 | 59 | female | 1 | 7 | 5.4 | 1 | osimertinib 80 mg daily | 20.1 | false | MSS | 2026-03-15T05:35:57.102757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999520 | REC_0001057 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 17 | 12 | 70 | female | 1 | 17 | 4.9 | 0 | entrectinib 600 mg daily | 40.2 | false | MSS | 2026-03-15T05:35:57.102991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876951 | REC_0001058 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 12 | 12.5 | 63 | male | 0 | 7 | 6 | 8 | osimertinib 80 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:35:57.103224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273234 | REC_0001059 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 7.3 | 69 | female | 0 | 11 | 7 | 1 | osimertinib 80 mg daily | 15.7 | true | MSS | 2026-03-15T05:35:57.103455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264323 | REC_0001060 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 16.7 | 71 | male | 1 | 8 | 5.5 | 4 | sotorasib 960 mg daily | 5.3 | false | MSI-H | 2026-03-15T05:35:57.103705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520448 | REC_0001061 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 14.1 | 66 | female | 1 | 12 | 5 | 1 | sotorasib 960 mg daily | 16.9 | false | MSS | 2026-03-15T05:35:57.103950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677661 | REC_0001062 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 32 | 15.2 | 64 | male | 0 | 12 | 5.7 | 0 | alectinib 600 mg BID | 26.8 | false | MSS | 2026-03-15T05:35:57.104278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902286 | REC_0001063 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.6 | 67 | female | 0 | 21 | 4.4 | 5 | osimertinib 80 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:35:57.104549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916920 | REC_0001064 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 6.9 | 69 | male | 0 | 22 | 4.2 | 2 | pembrolizumab 200 mg q3w | 23.9 | false | MSS | 2026-03-15T05:35:57.104809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823859 | REC_0001065 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7 | 73 | female | 2 | 45 | 8.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.6 | false | MSS | 2026-03-15T05:35:57.105079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507001 | REC_0001066 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 14.4 | 77 | female | 2 | 14 | 6 | 4 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:57.105341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915094 | REC_0001067 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 13.7 | 59 | female | 0 | 11 | 5.6 | 0 | osimertinib 80 mg daily | 15.1 | true | MSI-H | 2026-03-15T05:35:57.105701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949181 | REC_0001068 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.9 | 62 | male | 0 | 10 | 4.6 | 6 | sotorasib 960 mg daily | 4.2 | false | MSI-H | 2026-03-15T05:35:57.105952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879407 | REC_0001069 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 18 | 16.9 | 70 | female | 2 | 14 | 5.8 | 0 | osimertinib 80 mg daily | 33.4 | true | MSI-H | 2026-03-15T05:35:57.106191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338216 | REC_0001070 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 10.3 | 71 | female | 2 | 8 | 4.5 | 2 | osimertinib 80 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:35:57.106425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350468 | REC_0001071 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 16.8 | 68 | female | 0 | 24 | 5 | 2 | alectinib 600 mg BID | 7.4 | false | MSS | 2026-03-15T05:35:57.106659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402239 | REC_0001072 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 6.2 | 55 | male | 0 | 14 | 6.9 | 1 | alectinib 600 mg BID | 11.8 | false | MSS | 2026-03-15T05:35:57.106893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615633 | REC_0001073 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.8 | 70 | female | 2 | 53 | 4.9 | 8 | carboplatin + paclitaxel + pembrolizumab | 17.5 | false | MSS | 2026-03-15T05:35:57.107122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260860 | REC_0001074 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 10.4 | 75 | female | 1 | 10 | 4.8 | 5 | osimertinib 80 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:57.107354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738246 | REC_0001075 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 15.7 | 68 | female | 0 | 16 | 3.3 | 2 | osimertinib 80 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:57.107590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634442 | REC_0001076 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.8 | 60 | male | 1 | 34 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.3 | false | MSS | 2026-03-15T05:35:57.107836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558484 | REC_0001077 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 6.5 | 56 | male | 1 | 22 | 3 | 3 | entrectinib 600 mg daily | 12 | false | MSS | 2026-03-15T05:35:57.108128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406021 | REC_0001078 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 12.5 | 65 | female | 0 | 15 | 5.9 | 5 | entrectinib 600 mg daily | 16.8 | false | MSS | 2026-03-15T05:35:57.108390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901049 | REC_0001079 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.2 | 85 | female | 1 | 64 | 4.9 | 8 | carboplatin + paclitaxel + pembrolizumab | 15 | false | MSS | 2026-03-15T05:35:57.108643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260502 | REC_0001080 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 19.7 | 55 | female | 1 | 18 | 6.9 | 6 | alectinib 600 mg BID | 13.3 | false | MSI-H | 2026-03-15T05:35:57.108974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121503 | REC_0001081 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 11.6 | 75 | male | 0 | 21 | 7.2 | 6 | alectinib 600 mg BID | 10.8 | true | MSS | 2026-03-15T05:35:57.109219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482816 | REC_0001082 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 12.2 | 79 | female | 1 | 8 | 5.7 | 5 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.109456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588459 | REC_0001083 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 15 | 16.1 | 70 | female | 1 | 8 | 6.9 | 4 | sotorasib 960 mg daily | 6.9 | true | MSS | 2026-03-15T05:35:57.109691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572452 | REC_0001084 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 10.3 | 71 | female | 3 | 13 | 5.5 | 1 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.109927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820629 | REC_0001085 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 4.4 | 80 | female | 1 | 27 | 4 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.4 | true | MSS | 2026-03-15T05:35:57.110161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503558 | REC_0001086 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 8.5 | 61 | female | 1 | 9 | 7.9 | 6 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:35:57.110392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855318 | REC_0001087 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.8 | 56 | female | 1 | 7 | 6.1 | 6 | entrectinib 600 mg daily | 18.6 | true | MSI-H | 2026-03-15T05:35:57.110630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532051 | REC_0001088 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.3 | 62 | male | 1 | 14 | 5.4 | 2 | osimertinib 80 mg daily | 19.6 | true | MSI-H | 2026-03-15T05:35:57.110865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331012 | REC_0001089 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 12.6 | 68 | female | 0 | 18 | 3 | 5 | sotorasib 960 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:57.111096+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752500 | REC_0001090 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.9 | 68 | female | 1 | 12 | 3.6 | 4 | entrectinib 600 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:57.111327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165656 | REC_0001091 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 9.6 | 78 | female | 1 | 12 | 5.5 | 7 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:57.111557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422598 | REC_0001092 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 3.8 | 72 | female | 1 | 11 | 3.6 | 3 | alectinib 600 mg BID | 5.8 | true | MSS | 2026-03-15T05:35:57.111823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880724 | REC_0001093 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 9.4 | 59 | female | 0 | 10 | 5.2 | 1 | osimertinib 80 mg daily | 15.8 | true | MSS | 2026-03-15T05:35:57.112212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838620 | REC_0001094 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5 | 62 | female | 1 | 61 | 4.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 21.6 | false | MSS | 2026-03-15T05:35:57.112467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451086 | REC_0001095 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 4.3 | 81 | female | 3 | 11 | 6.2 | 2 | entrectinib 600 mg daily | 20.8 | true | MSS | 2026-03-15T05:35:57.112705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676431 | REC_0001096 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 15.1 | 61 | female | 0 | 21 | 6.5 | 5 | alectinib 600 mg BID | 16.5 | false | MSI-H | 2026-03-15T05:35:57.112941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190989 | REC_0001097 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 5.7 | 74 | female | 2 | 7 | 4.3 | 2 | sotorasib 960 mg daily | 27.4 | false | MSS | 2026-03-15T05:35:57.113171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739540 | REC_0001098 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 7.9 | 73 | male | 3 | 13 | 8.8 | 7 | alectinib 600 mg BID | 13.7 | true | MSS | 2026-03-15T05:35:57.113405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579548 | REC_0001099 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 15.5 | 59 | female | 1 | 15 | 6.7 | 2 | osimertinib 80 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:57.113641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828067 | REC_0001100 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 12.1 | 66 | female | 0 | 15 | 5.6 | 0 | osimertinib 80 mg daily | 23.6 | false | MSS | 2026-03-15T05:35:57.113885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.